Premium
Combination chemotherapy in metastatic malignant melanoma. A randomized study of three DTIC‐containing combinations
Author(s) -
Wittes Robert E.,
Wittes Janet T.,
Golbey Robert B.
Publication year - 1978
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197802)41:2<415::aid-cncr2820410206>3.0.co;2-s
Subject(s) - procarbazine , medicine , nausea , vinblastine , dacarbazine , chemotherapy , cyclophosphamide , randomized controlled trial , vomiting , lomustine , combination chemotherapy , oncology , surgery , vincristine , gastroenterology
The activity of three DTIC‐containing combinations was compared in a prospective randomized study. Of 101 patients randomized to receive one of the three regimens, 95 received adequate trials. Response rates were as follows: DTIC+cyclophosphamide 7/29 (24%); DTIC+vinblastine 6/34 (18%); DTIC+procarbazine 4/32 (13%). None of these response rates is significantly superior to any of the others. When the activity of the combination is analyzed by sex, DTIC+cyclophosphamide appears more active in females than the other regimens, but the difference is not statistically significant. Response to treatment is associated with significant prolongation of life; the median survival among responders was 11 months, while those who progressed lived a median of 4 months from the start of therapy. Toxicity of all regimens appeared to be about the same; therapy with DTIC+procarbazine was associated with significantly more nausea and vomiting. This study has failed to demonstrate clearly that any of three combinations is superior to any of the others.